$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer

2010-11

2016-03

2016-03

44

Study Overview

AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer

The purpose of this study is to assess the effect and safety of AXP107-11 alone, and in combination with gemcitabine standard therapy, in patients with advanced or metastatic cancer of the pancreas. The safety, pharmacokinetics and efficacy of AXP107-11 in these patients will also be studied.

The annual incidence rate of pancreatic cancer is almost identical to the mortality rate. Despite a low incidence rate, pancreatic cancer is the fourth leading cause of cancer mortality in both men and women. Today is the only potentially curative option of these patients complete surgical resection. However, a majority of the patients (up to 80%) are not eligible for surgery for different reasons. Today is gemcitabine the accepted first-line treatment for these patients. Recent advances in the management of pancreatic cancer suggest that gemcitabine may be improved by combining it with other anticancer drugs. One attractive therapeutic option is genistein. Genistein appears to sensitize tumors to chemotherapy both by targeting the tumor cells and also by targeting components of the tumor microenvironment. However, the limited bioavailability of genistein in its known crystalline form has led to difficulties in attaining adequate plasma concentration, resulting in limited application and dissemination in the clinical setting. To overcome this limitation, a novel crystalline form of genistein with improved pharmaceutical properties is being used. AXP107-11, a crystalline salt of genistein has improved physiochemical properties (solubility, dissolution rate, bioavailability) as compared to the known crystalline form of genistein. In this study, AXP107-11, will be investigated alone and in combination with gemcitabine in patients with pancreatic cancer.

  • Adenocarcinoma
  • DRUG: AXP107-11
  • AXP-CT-001

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2010-08-04  

N/A  

2014-04-22  

2010-08-13  

N/A  

2014-04-23  

2010-08-16  

N/A  

2014-04  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: AXP107-11

DRUG: AXP107-11

  • The drug substance, AXP107-11, is a crystalline form of genistein, a substance shown in literature data to target pancreatic tumor cells and also the tumor microenvironment and thus sensitizes tumors to chemotherapy. AXP107-11 is formulated in a capsule c
Primary Outcome MeasuresMeasure DescriptionTime Frame
Determine the safety profile and the maximum tolerated dose (MTD) of AXP107-11 alone and when given in combination with gemcitabine standard therapy.Safety (AEs, dose limiting toxicity, laboratory tests, vital signs, weight and ECG). MTD is defined at day 8.up to 6 months
To assess the effect of a combination therapy of AXP107-11 and gemcitabine on objective response rate defined as the percentage of patients who showed complete response (CR) or partial response (PR).The tumour response evaluation will be performed according to RECIST (www.recist.org)up to 6 months
Secondary Outcome MeasuresMeasure DescriptionTime Frame
To determine the pharmacokinetic (PK) profile of escalating doses of AXP107-11.Plasma concentration of AXP107-11Day -13, 1, 8 and 15
To assess the safety and tolerability of a combination therapy of AXP107-11 and gemcitabine.Assessed by occurrence of adverse events, abnormal changes in laboratory parameters, vital signs, ECG, relevant patient withdrawal and percentage of patients having reduction, omission or discontinuation of any study medication. Note: This is a secondary outcome measurement for patients in the phase IIa part of the study. This is a primary objective in phase Ib.up to 6 months
To assess the effect of a combination therapy of AXP107-11 and gemcitabine on overall survival (OS).up to 6 months
To assess the effect of a combination therapy of AXP107-11 and gemcitabine on overall survival rate at six months after start of combination therapy.up to 6 months
To assess the effect of a combination therapy of AXP107-11 and gemcitabine on time to progression (TTP).up to 6 months
To assess the effect of a combination therapy of AXP107-11 and gemcitabine on palliation, defined as the percentage of patients who showed CR, PR or stable disease (SD).The tumour response evaluation will be performed according to RECIST (www.recist.org)up to 6 months
To assess the effect of a combination therapy of AXP107-11 and gemcitabine on clinical benefit response, a composite of measurements of pain (pain intensity and analgesics consumption), Karnofsky performance status and weight.up to 6 months
To assess the effect of combination therapy of AXP107-11 and gemcitabine on the tumor mass using F-18 fluorodeoxyglucose positron emission tomography (FDG-PET).Will be performed on the first 5 patients in the phase IIa part of the study.up to 6 months
To assess the effect of a combination therapy of AXP107-11 and gemcitabine on symptom distress score as measured by the Edmonton Symptom Assessment System (ESAS).up to 6 months
To assess the effect of a combination therapy of AXP107-11 and gemcitabine on quality of life as assessed by the EORTC QLQ-C30 questionnaire and the PAN26 module.up to 6 months

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. Age ≥ 18 years at the time of signing the informed consent 2. Histologically confirmed adenocarcinoma of the pancreas 3. Metastatic or locally advanced, unresectable disease stage III-IV. 4. Measurable disease according to the international criteria proposed by the Response Evaluation Criteria in Solid tumors (RECIST) for target lesions 5. Karnofsky Performance Status ≥ 70 at study entry (Appendix 18.4). 6. Life expectancy of more than three months 7. Negative pregnancy test for female patients 8. For fertile women, willingness to perform double-barrier contraception during study and for four weeks after last treatment 9. Able and willing to sign the informed consent form
    Exclusion Criteria:
    1. Previous or ongoing severe supraventricular or ventricular arrhythmia 2. Previous or ongoing coagulation or bleeding disorder (PTT > 1.5 x ULN) 3. HIV infection 4. Known hypersensitivity to any component of the AXP107-11 formulation or gemcitabine 5. Previous or ongoing significant liver pathology (other than metastases) and/or liver function disorders 6. Previous or ongoing significant chronic renal dysfunction 7. Previous or ongoing malignancy other than pancreatic cancer < five years prior to enrolment, except basal cell carcinoma treated locally 8. Cardiovascular disease, New York Heart Association (NYHA) classification III or IV16 9. Severe pulmonary obstructive or restrictive disease 10. Acute or chronic inflammation (autoimmune or infectious) 11. Significant active/unstable non-malignant disease likely to interfere with study assessments 12. Laboratory tests (hematology, chemistry) outside specified limits:

  • WBC ≤ 3 x 10³/mm³
  • ANC ≤ 1.5 x 10³/mm³
  • Platelets ≤ 100.000/mm³
  • Hb ≤ 9.0 g/dl (≤ 5.6 mmol/l)
  • PT/PTT > 1.5 x ULN
  • Serum creatinine > 130 μmol/l) or clearance < 60 ml/min
  • AST and/or ALT > 3 x ULN with the exception of patients with liver metastasis (> 5 x ULN)
  • Alkaline phosphatase > 3 x ULN
  • Total bilirubin > 3 x ULN 13. Immunotherapy within six weeks prior to enrolment. 14. Any chemotherapeutical treatment for pancreatic adenocarcinoma before enrolment 15. Any radiotherapy for pancreatic adenocarcinoma before enrolment except for treatment of bone metastases if target lesions are not included in the irradiated field 16. Major surgery within four weeks prior to enrolment 17. Pregnant or nursing woman 18. Participations in other interventional clinical study within four weeks of enrolment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

    • PRINCIPAL_INVESTIGATOR: Mattias Löhr, MD,PhD, Prof., Karolinska Institutet

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available

    NPCF Pop up

    Make-A-Will Month

    Snag 6508be92
    Learn More
    Donate Now Online
    Other Ways to Donate